SCHEDULE 13G: Intracoastal Capital and Affiliates Disclose 9.99% Passive Stake in Processa Pharmaceuticals

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a passive beneficial ownership of 9.99% in Processa Pharmaceuticals, Inc.'s common stock.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed a Schedule 13G, disclosing their beneficial ownership in Processa Pharmaceuticals, Inc.
• As of June 20, 2025, the Reporting Persons collectively beneficially owned 3,018,238 shares of Processa Pharmaceuticals' common stock.
• This aggregate amount represents approximately 9.99% of the company's outstanding common stock.
• The ownership includes 2,430,000 shares of Common Stock held by Intracoastal, 260,000 shares issuable upon exercise of Intracoastal Warrant 1, and 328,238 shares issuable upon exercise of Intracoastal Warrant 2.
• The beneficial ownership percentage is calculated based on 11,884,356 shares outstanding as of June 10, 2025, plus shares issued and issuable from the recent transaction.
• The filing indicates shared voting power over 3,018,238 shares and shared dispositive power over 588,238 shares, with no sole voting or dispositive power.
• The beneficial ownership is subject to blocker provisions in the warrants, preventing exercise if it would result in ownership exceeding 9.99% of the common stock.
• Without these blocker provisions, the Reporting Persons could have been deemed to beneficially own up to 7,690,000 shares as of June 20, 2025, or 10,000,000 shares immediately following the Securities Purchase Agreement on June 17, 2025.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by an institutional investor is generally a positive signal, indicating confidence in the company. The nature of a 13G filing is purely informational, but the underlying transaction (capital raise) is positive for the company.

Positives

• A significant institutional investor, Intracoastal Capital LLC, has taken a substantial 9.99% stake in Processa Pharmaceuticals, which can be viewed as a vote of confidence in the company's future prospects.
• The investment was made through a Securities Purchase Agreement, indicating a structured transaction and potentially providing capital to the company.

Risks

• The beneficial ownership is capped at 9.99% due to blocker provisions in the warrants, which limits the immediate upside from full warrant exercise for the Reporting Persons and could indicate a desire to avoid certain regulatory or governance thresholds.
• The filing explicitly states that the securities were not acquired for the purpose of changing or influencing control of the issuer, indicating a passive investment strategy, which may not lead to active engagement in improving company performance.

Future Outlook

The document does not provide specific forward-looking statements or guidance from Processa Pharmaceuticals, Inc. It primarily details the current beneficial ownership stake of the Reporting Persons.

Industry Context

This filing indicates a significant passive investment by an institutional entity in a pharmaceutical company. Such investments are common in the biotechnology and pharmaceutical sectors, where companies often rely on external capital for research, development, and operational funding. A substantial stake by an investor like Intracoastal Capital can signal market confidence in the company's drug pipeline or strategic direction, potentially attracting further investor interest.

Comparison to Industry Standards

• A 9.99% beneficial ownership stake is a substantial passive investment, often chosen by institutional investors to gain significant exposure to a company without triggering the 10% threshold that typically requires more extensive regulatory disclosures (e.g., Schedule 13D) or potential activist investor classification.
• The use of blocker provisions in warrants to maintain ownership below a specific threshold (9.99% in this case) is a common strategy employed by investors to avoid becoming an 'insider' or 'affiliate' for certain regulatory purposes, while still retaining the potential for future equity upside.

Stakeholder Impact

• **Shareholders**: The entry of a new significant institutional investor may be viewed positively, potentially increasing investor confidence and liquidity. The capital raise associated with this investment could also strengthen the company's financial position.
• **Company Management**: The investment provides capital, which can support ongoing operations, research, and development initiatives. The passive nature of the investment suggests no immediate pressure for management changes or strategic shifts from this investor.

Key Dates

Keywords

Processa Pharmaceuticals, Intracoastal Capital, Schedule 13G, Beneficial Ownership, Common Stock, Equity Stake, Institutional Investment, Warrants, Biotechnology, Pharmaceuticals